Zentalis prices public offering of 11M shares at $22.66, raising ~$235.5M

Zentalis Pharmaceuticals, Inc.

Sale of 11,032,656 common shares at $22.66 per share; net proceeds estimated at $235.5M.
Net proceeds to be used for ongoing and planned clinical trials and working capital.
Closing expected on June 20, 2023, subject to customary conditions.
Underwriters include Morgan Stanley, Jefferies, and SVB Securities.
Offering conducted under effective shelf registration statement on Form S-3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.